过氧化物酶体增殖物激活受体激动剂罗格列酮对人子宫肌瘤细胞的影响
摘要
目的：
通过不同浓度过氧化物酶体增殖物激活受体激动剂罗格列酮作用于人体外子宫肌瘤细胞后,观察对人子宫肌瘤细胞的增值抑制及对过氧化物酶体增殖物激活受体(PPARy)和凋亡基因Bax、Bcl-2表达的影响,来探讨子宫肌瘤可能的发生机制及能否抑制子宫肌瘤的生长,并提示临床应用PPARγ激动剂治疗子宫肌瘤的潜在可能。
方法：
应用胶原酶消化法分离、获得子宫肌瘤细胞,用鼠抗人平滑肌肌动蛋白(a-actin)进行免疫细胞化学法鉴定。给予原代培养的子宫肌瘤不同浓度的罗格列酮处理,以四甲基偶氮唑盐微量酶反应比色(MTT)法测定细胞生长抑制率；以半定量逆转录聚合酶链反应(RT-PCR)法检测PPARymRNA以及凋亡基因Bax、Bcl-2在子宫肌瘤细胞中的表达及罗格列酮对子宫肌瘤细胞增殖活化的影响。
结果：
(1)应用消化法获得了大量原代子宫肌瘤细胞,并通过免疫化学细胞证实。
(2)MTT法结果显示：不同浓度罗格列酮作用24h,对子宫肌瘤细胞的增值无明显抑制,差异无统计学意义(P>0.05)；不同剂量的罗格列酮作用48h、72h后对各实验组子宫肌瘤细胞的增值有明显的抑制,与相同条件下作用24h的子宫肌瘤细胞的增值抑制率相比具有明显的差异(P<0.05)；而且各组之间细胞增殖抑制率差异有统计学意义(P<0.05)。5×10-8mol／L罗格列酮作用子宫肌瘤各个时间点对子宫肌瘤的增值无明显抑制,差别无统计学意义P>0.05);而相同剂量(5×10-6,5×10-7mol／L)的罗格列酮作用子宫肌瘤,随作用时间的延长对各实验组子宫肌瘤细胞的增值有明显的抑制(P<0.05)；而且各组之间细胞增殖抑制率差异有统计学意义(P<0.05)。这种抑制作用存在剂量和时间依赖性。
(3)半定量RT-PCR结果显示：罗格列酮(5×10-6、5×10-7、5×10-8mol／L)作用于子宫肌瘤细胞72h后,可明显升高加药组细胞PPARγ, Bax的表达水平,下调Bcl-2的表达水平,呈剂量依赖性。表现出明显活化抑制。
结论：
(1)罗格列酮可显著抑制体外培养的人子宫肌瘤细胞增殖,随着药物剂量的增加和时间的延长,子宫肌瘤细胞的增殖和活化明显抑制,呈剂量和时间依赖性。
(2)罗格列酮通过激活PPARy抑制子宫肌瘤细胞的增值可能是通过上调Bax,下调Bcl-2的表达实现的。
(3)罗格列酮用于子宫肌瘤的治疗可能具有潜在价值。
Objective:
To explore the leiomyoma cells growth inhibition induced by a peroxisome proliferator activated receptor-Y activator rosiglitazone and its molecular mechanism.and to explore the expression of PPARγ、Bax、Bcl-2 mRNA, and the suppressive effect of rosilitazone on the proliferation and apoptosis of uterine leiomyoma cells in vitro. Our purpose was to explore the possible mechanism of uterine leiomyoma, and the possible to inhibit the growth of uterine leiomyoma, and prompt clinical application of PPAR Y agonist treatment of uterine leiomyma potential.
Methods:
Uterine leiomyoma cells were cultered in vitro,after the action of rosigliatzone with different concentration,MTT was used to examne the inhibition activity of uterine leiomyoma cells.RT-PCR was used to determine the expression of the PPARγand of the apoptosi genes Bax、Bcl-2 in uterine leiomyoma.
Result:
(1)The uterine leiomyma cells were got by using collagenase dissection and identified by immunocytochemistry.
(2)MTT method showed that:The treatment after2、48、72h(P< 0.05) resulted in an inhibition of the cell growths with (5 X 10-6、5×10-7 mol/L) rosiglitazone(P< 0.05),and there were no significant difference between eath other with 5 X 10-8mol/Lrosiglitazone (P> 0.05). The treatment with rosiglitazone(5 X 10-6、5 X 10-7、5 X 10-8mol/L) resulted in an inhibition of the cell growths after 72、48 house (P< 0.05),and there were no significant difference between each other in the treatment of 24h(P> 0.05).
(3)Semi-quantitative RT-PCR results showed that:Rosiglitazone(5 X 10-6、5 X 10-7、5 X 10-8mol/L) affect uterine leiomyma cells 72h,will increase the expression of PPARγ,Bax,reduce the expression of Bcl-2,and its role is adose dependent manner., showing apparent activation inhibition.
Conclusion:
(1)Rosiglitazone significantly inhibited the in vitro cultured human uterine leiomyoma cell proliferation, with the increase in drug dose and the extension of the time, uterine leiomyoma cell proliferation and activation are inhibited, show a dose-and time-dependent.
(2) Rosiglitazone can suppress the cell proliferation partly through the regulations of PPAR-γ、Bax and Bcl-2 expressions. The cross-talk between the signal pathways of PPAR-y and Bax、Bcl-2 may be involved in the process.
(3)PPARγligands may be of potential use for uterine leiomyoma treantment.
通过不同浓度过氧化物酶体增殖物激活受体激动剂罗格列酮作用于人体外子宫肌瘤细胞后,观察对人子宫肌瘤细胞的增值抑制及对过氧化物酶体增殖物激活受体(PPARy)和凋亡基因Bax、Bcl-2表达的影响,来探讨子宫肌瘤可能的发生机制及能否抑制子宫肌瘤的生长,并提示临床应用PPARγ激动剂治疗子宫肌瘤的潜在可能。
方法：
应用胶原酶消化法分离、获得子宫肌瘤细胞,用鼠抗人平滑肌肌动蛋白(a-actin)进行免疫细胞化学法鉴定。给予原代培养的子宫肌瘤不同浓度的罗格列酮处理,以四甲基偶氮唑盐微量酶反应比色(MTT)法测定细胞生长抑制率；以半定量逆转录聚合酶链反应(RT-PCR)法检测PPARymRNA以及凋亡基因Bax、Bcl-2在子宫肌瘤细胞中的表达及罗格列酮对子宫肌瘤细胞增殖活化的影响。
结果：
(1)应用消化法获得了大量原代子宫肌瘤细胞,并通过免疫化学细胞证实。
(2)MTT法结果显示：不同浓度罗格列酮作用24h,对子宫肌瘤细胞的增值无明显抑制,差异无统计学意义(P>0.05)；不同剂量的罗格列酮作用48h、72h后对各实验组子宫肌瘤细胞的增值有明显的抑制,与相同条件下作用24h的子宫肌瘤细胞的增值抑制率相比具有明显的差异(P<0.05)；而且各组之间细胞增殖抑制率差异有统计学意义(P<0.05)。5×10-8mol／L罗格列酮作用子宫肌瘤各个时间点对子宫肌瘤的增值无明显抑制,差别无统计学意义P>0.05);而相同剂量(5×10-6,5×10-7mol／L)的罗格列酮作用子宫肌瘤,随作用时间的延长对各实验组子宫肌瘤细胞的增值有明显的抑制(P<0.05)；而且各组之间细胞增殖抑制率差异有统计学意义(P<0.05)。这种抑制作用存在剂量和时间依赖性。
(3)半定量RT-PCR结果显示：罗格列酮(5×10-6、5×10-7、5×10-8mol／L)作用于子宫肌瘤细胞72h后,可明显升高加药组细胞PPARγ, Bax的表达水平,下调Bcl-2的表达水平,呈剂量依赖性。表现出明显活化抑制。
结论：
(1)罗格列酮可显著抑制体外培养的人子宫肌瘤细胞增殖,随着药物剂量的增加和时间的延长,子宫肌瘤细胞的增殖和活化明显抑制,呈剂量和时间依赖性。
(2)罗格列酮通过激活PPARy抑制子宫肌瘤细胞的增值可能是通过上调Bax,下调Bcl-2的表达实现的。
(3)罗格列酮用于子宫肌瘤的治疗可能具有潜在价值。
Objective:
To explore the leiomyoma cells growth inhibition induced by a peroxisome proliferator activated receptor-Y activator rosiglitazone and its molecular mechanism.and to explore the expression of PPARγ、Bax、Bcl-2 mRNA, and the suppressive effect of rosilitazone on the proliferation and apoptosis of uterine leiomyoma cells in vitro. Our purpose was to explore the possible mechanism of uterine leiomyoma, and the possible to inhibit the growth of uterine leiomyoma, and prompt clinical application of PPAR Y agonist treatment of uterine leiomyma potential.
Methods:
Uterine leiomyoma cells were cultered in vitro,after the action of rosigliatzone with different concentration,MTT was used to examne the inhibition activity of uterine leiomyoma cells.RT-PCR was used to determine the expression of the PPARγand of the apoptosi genes Bax、Bcl-2 in uterine leiomyoma.
Result:
(1)The uterine leiomyma cells were got by using collagenase dissection and identified by immunocytochemistry.
(2)MTT method showed that:The treatment after2、48、72h(P< 0.05) resulted in an inhibition of the cell growths with (5 X 10-6、5×10-7 mol/L) rosiglitazone(P< 0.05),and there were no significant difference between eath other with 5 X 10-8mol/Lrosiglitazone (P> 0.05). The treatment with rosiglitazone(5 X 10-6、5 X 10-7、5 X 10-8mol/L) resulted in an inhibition of the cell growths after 72、48 house (P< 0.05),and there were no significant difference between each other in the treatment of 24h(P> 0.05).
(3)Semi-quantitative RT-PCR results showed that:Rosiglitazone(5 X 10-6、5 X 10-7、5 X 10-8mol/L) affect uterine leiomyma cells 72h,will increase the expression of PPARγ,Bax,reduce the expression of Bcl-2,and its role is adose dependent manner., showing apparent activation inhibition.
Conclusion:
(1)Rosiglitazone significantly inhibited the in vitro cultured human uterine leiomyoma cell proliferation, with the increase in drug dose and the extension of the time, uterine leiomyoma cell proliferation and activation are inhibited, show a dose-and time-dependent.
(2) Rosiglitazone can suppress the cell proliferation partly through the regulations of PPAR-γ、Bax and Bcl-2 expressions. The cross-talk between the signal pathways of PPAR-y and Bax、Bcl-2 may be involved in the process.
(3)PPARγligands may be of potential use for uterine leiomyoma treantment.
引文
[1].Borrmann L, Wilkening S, Bullerdiek J.The expression of HMGA genes is regulated by their3'UTR.Oneogene,2001,20(33):4537-41.
[2].GaoZ, MatsuoH, WangY, et al.UP-regulation by IGF-1 of proliferating cell nuclear antigen and Bcl-2protein expression inhuman uterine leiomyomata cells. J Clin EndocrinolMetab,2001, 86(11):5593-9.
[3].Vu Th, Yballe C, Boonyanit S, et al.Insulin-like growth faetorⅡin uterine smooth musele tumors maintenance of genomic imprinting in leiomyoma and loss of imprinting in leiom--yosarcomata.J Clin Endoerinol Metab,1995,80(5):1670-6.
[4].DouQ,ZhaoY,RoyW,et al.Suppression of transforming growth factor-beta (TGFbeta) and TGF beta receptor messenger ribonueleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy.J Clin Endoerinol Metab,1996, 81(9):3222-30.
[5].Edenberg HJ.Regulation of the mammalian alcohol dehydrogenase genes.Prog NueleieAcid Res MolBiol,2000,64:295-341.
[6].Sun H, Berquin IM, et al. Peroxisome proliferaor-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3fatty acids promotes apoptosis of human breast cancer cells. Cancer Res.2008 Apr 15;68(8):2912-9.
[7].Ma XM, Yu H, et al. Peroxisome proliferator-acticated receptor-gamma is essential in zhe pathogenesis of gastric carcinoma. World J Gastroenterol.2009 Aug 21; 15(15):3874-83.
[8].ChenW, Yang CC, Sheu HM, et al. Expression of peroxisome proliferator-activated reeeptor and CCAAT/enhancer binding protein transcription factors in cultured human seboeytes. J Invest Dermatol,2003,121(3):441-7.
[9].Arslan AA, Gold LI, Mittal K, et al.Gene expression studies provide clues to the pathogenesis of uterine leiomyoma:new evidence and a systematic review.HumReprod,2005, 20(4):852-63.
[10].Chun-hua ZHANG, Ze-qing WEN, et al. Inhibition of proliferation and transforming growth factors β 3 protein expression by peroxisome proliferators-activated receptor γ ligands in human uterine leiomyoma cells. Chin Med J,2008,121(2):166-171.
[11].Houston KD, CoPland JA, BroaddusRR, et al Inhibition of proliferation and estrogen rceeptor signaling by Peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma.Caneer Res,2003,63(6):1221-7.
[12].Jones SA, Moore LB, Shenk JL, ET AL. The pregnane X receptor:a promiseuous xenobiotic receptor that has diverged during evolution. MolEndoerinal,2000,14(1):27-39.
[13].Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome proliferators-activated receptors (PPARs) and their roles in inflam-mation and cancer [J]. Cell Mol Life Sci,1999,55:932-43
[14].Yu D, Murdoch SJ, Parikh SJ, et al. rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diab Vasc Dis Res,2006,3(3):189-96.
[15].Rios-Vazquez R, Marzoa-Rivas R, Gil-Ortega I. et al. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs.2006,6(4):231-42
[16].Freed MI, Allen A, Jorkasky DK, et al. Systemic exposure to rosiglitazone is unaltered by food. Eur J Clin Pharmacol,1999,55(1):53-56.
[17].Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos,2000,28(7):772-80.
[18]Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Er J Clin Pharmaccl,1999,48(3):424-32.
[19].Thompson-Culkin K, Zussman B, Miller A, et al. Pharmacokinetics of rosiflitazone in patients with end-stage renal disease. J Int Med Res,2002,30(4):391-399.
[20].Stumvoll M, Haring HU. Glitazones:clinical effects and molecular mechanisms. Ann Med, 2002,34(3):217-24.
[21].Ehrmann JJr,Vavrusova N,Collan Y, et al. Peroxisome proliferators activated-receptors(PPARs) in health and disease.Biomed Pad Med Fac Univ Palacky Olomouc Czech Rupub,2002,146(2):11-14.
[22].Wood DE,Thomas A, Devi,et al.Bax cleavage is mediated by calpain during drug induced apoptosis.Oncogene,1998,17:1069-1078.
[23].Kovacs KA,Lengyel F, Kornyei JL,et al. Differential espression of Akt/protein kinase B,bcl-2 and bas proteins in human leiomyoma and myometrium.J Steroid Biochem Mol Biol,2003,87(4250;233-40.
[24].Matsuo H,Maruo T,Samoto T. Increased expression of bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab,1997,82 (1):293-99.
[25].Wu X, Blanck A,OlovssonM, et al. Expression of bcl-2,bcl-x,mcl-l,bax and bak in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause.J Steroid Biochem Mol Biol,2002,80(1):77-83.
[1].Issemannl, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature,1990,347(6294):645-50.
[2].Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996,1302(2):93-109.
[3].Elbrecht A, Chen Y, Cullinan CA, et al. Molecular cloning expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun,1996,224(2):431-37.
[4]Willson TM,Brown PJ, Sternbach DD, et al. The PPARs:from orphan receptors to drug discovery. J Med Chem,2000,43 (4):527-50.
[5].Forman BM, Tontonoz P, Chen J, et al.15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell,1995,83(5):803-12.
[6].Berger J,Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator activated receptor-gamma:binding and activation correlate with antidiabetic actions in db/db mice.Endocrinology.1996.137(10):4189-95.
[7].HOUSEKNECHT KL, COLEBM, STEELE PJ. Peroxisome proliferators-activated receptor gamma and review. Domest Anim Endocrinol,2002,22(1):1-23.
[8].Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol,2002,2(10):748-59.
[9]. Castrillo A,Diaz-Guerra MJ, Hortelano S, et al. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta (12,14)-prostaglandin J (2) in activated murine macro-phages. Mol Cel 1 Biol,2000,20 (5):1692-98.
[10]. Palakurthi SS, Aktas H, Grubissich LM, et al. Anticancer effect s of thiazolidinediones are independent of peroxisome proliferators-activated receptor gamma and mediated by inhibit-tion of translation initiation. Cancer Res,2001,61 (16):6213-18.
[11].Zander T, Kraus JA, Grommes C, et al. Induction of apoptosis in hunman and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem,2002,81(5):1052-60.
[12].杨风光,张志文,辛殿祺,等。曲格列酮诱导肾癌细胞的凋亡.北京大学学报(医学版),2004,36(2)：173-176.
[13].Nagamine M,Okumura T, Tanno S, et al. PPAR γ ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci,2003,94 (4):338-43.
[14].Baek SJ, Wilson LC, His LC, et al. Troglitazone, a peroxisome proliferator-activated receptor γ (PPAR Y) ligand, selectively induces the early growth responser-1 gene independently of PPAR γ. J Biol Chen,2003,278(8):5845-53.
[15].Piva R, Gianferretti P, Ciucci A, et al.15-Deoxy-{Delta} 12,14-prostaglandin J2 induces apoptosis in human malignant B cells:an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood,2005,105 (4):1750-58.
[16].Chung YW, Han DS, Kang EK, et al.Effects of peroxisome proliferators-activated receptor-gamma agonist on Fas-mediated apoptosis in HT229 cells. Korean J Gastroenterol,2003,42 (1):35-41.
[17].Strakova N, Ehrmann J, Dzubak P, et al. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther,2004,309 (3):1239-47.
[18].Han S, Sidell N, Fisher PB, et al. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res, 2004,10(6):1911-19.
[19]. Koga H, Sakisaka S, Harada M, et al. Involvement of p21(WAF1/Cip1), p27 (Kip1), and pl8(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology, 2001,33 (5):1087-97.
[20].潘华锋,陈孝平.Ciglitazone抑制人肝癌HepG2细胞增殖活性的实验研究.中华实验外科杂志,2004,21(8)：934-36.
[21].Kato M, Kusumi T, Tsuchida S, et al. Induction of differentiation and peroxisome prolife.rator-activator receptor γ expression in colon cancer cell lines by troglitazone. J. Cancer Res Clin Oncol,2004,130(2):73-79.
[22].Yoshizumi T, Ohta T, Nionmiya I, et al. Thiazolidine, a perroxisome proliferator-activated receptor-gammaligand, inhibits grows and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol,2004,25(3):631-39.
[23].Ceni E, Mello T, Tarocchi M, et al.Antidiabetic thiazolisinediones induce ductal differentiation but not apoptosis in pancreatic cancer cell. World J Gastroenterol, 2005,11 (8):1122-30.
[24].Zander T, Kraus JA, Grommes C, et al. induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgammma. J Neurochem,2002,81(5):1052-60.
[25]Barak Y, Nel son MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell,1999,4 (4):585-95.
[26]Margeli A, Kouraklis G, Theocharis S. Peroxisome proliferator activated receptor-c (PPAR-c) ligands and angiogenesis. Angiogenesis,2003,6 (3):165-69.
[27]Ferruzzi P, Ceni E, Tarocchi M, et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab,2005,90 (3):1332-39.
[28]Galli A, Ceni E, Crabb DW, et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR-gamma independent mechanisms.Gut,2004,53 (11):1688-97.
[29].Arslan AA, Gold LI, Mittal K, et al.Gene expression studies provide clues to the pathogenesis of uterine leiomyoma:new evidence and a systematic review.HumReprod,2005, 20(4):852-63.
[30].Chun-hua ZHANG, Ze-qing WEN, et al. Inhibition of proliferation and transforming growth factors β 3 protein expression by peroxisome proliferators-activated receptor γ ligands in human uterine leiomyoma cells. Chin Med J,2008,121(2):166-71.
[31].Houston KD, CoPland JA, BroaddusRR, et al Inhibition of proliferation and estrogen rceeptor signaling by Peroxisome proliferator-activated receptor gamma ligands in uterine leiomvoma.Caneer Res,2003,63(6):1221-27
[321Loy CJ, Evelyn S, Lim FK, et al. Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone. Mol Hum Reprod,2005;1:561-66
[33]Han S, Inoue H, Lisa C, et al. Control of COX2 gene expression through PPAR in human cervical cancer cells. Clin Cancer Res,2003,9:4627-4635.
[34]George G, Chen HX, J anet FY, et al.15-hydroxy-eicosate traenoic acidarrests growth of colorectal cancer cell s viaaperoxi some poliferator-activatedreceptor gamma-depengent pat-hway. Intern J Cancer,2003,107:837-843.
[35]阿仙姑·哈斯木,拉莱·苏组克,李巧稚,等.PPAR γ在人子宫肌瘤上皮内瘤样变中 表达及意义.新疆医科大学学报,2007,30(6)：601-603.
[36]Panigraphy D, Singer S, Shen LQ, et al. PPARr ligands inhibit primary tumor growth and metastasis by inhibit ingangio genesis. J Clin Invest,2002,110:923-932.
[37]Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system:Terminology for reporting result s of cervical cytology. JAMA,2002,287:2114-2119.
[38]Walker P, Dexeus S, De Palo G., et al. International Terminology of Colposcopy:An Updated Report From t he International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol,2003.101:175-177.
[39]孔蕾,张家文,于甬华,et al.PPAR、PTEN、P27kipl在雌激素依赖型和非雌激素依赖型子宫内膜癌中的表达及其临床意义.中国妇产科临床杂志,2007,Vol.8,No.6,442-44.
[40].Zhang GY, Ahmed N, Riley C. et al. Enhanced expression of perioxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer. 2005,92(1):113-9.
[41].Sakamoto A, Yokoyama Y, Umemnoto M. et al. Clinical implication of expression of cyclooxygenase-2 and peroxisome perliferator activated-receptor gamma in epithelial ovarian tumours. Br J Cancer.2004,91(4):633-638.
[2].GaoZ, MatsuoH, WangY, et al.UP-regulation by IGF-1 of proliferating cell nuclear antigen and Bcl-2protein expression inhuman uterine leiomyomata cells. J Clin EndocrinolMetab,2001, 86(11):5593-9.
[3].Vu Th, Yballe C, Boonyanit S, et al.Insulin-like growth faetorⅡin uterine smooth musele tumors maintenance of genomic imprinting in leiomyoma and loss of imprinting in leiom--yosarcomata.J Clin Endoerinol Metab,1995,80(5):1670-6.
[4].DouQ,ZhaoY,RoyW,et al.Suppression of transforming growth factor-beta (TGFbeta) and TGF beta receptor messenger ribonueleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy.J Clin Endoerinol Metab,1996, 81(9):3222-30.
[5].Edenberg HJ.Regulation of the mammalian alcohol dehydrogenase genes.Prog NueleieAcid Res MolBiol,2000,64:295-341.
[6].Sun H, Berquin IM, et al. Peroxisome proliferaor-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3fatty acids promotes apoptosis of human breast cancer cells. Cancer Res.2008 Apr 15;68(8):2912-9.
[7].Ma XM, Yu H, et al. Peroxisome proliferator-acticated receptor-gamma is essential in zhe pathogenesis of gastric carcinoma. World J Gastroenterol.2009 Aug 21; 15(15):3874-83.
[8].ChenW, Yang CC, Sheu HM, et al. Expression of peroxisome proliferator-activated reeeptor and CCAAT/enhancer binding protein transcription factors in cultured human seboeytes. J Invest Dermatol,2003,121(3):441-7.
[9].Arslan AA, Gold LI, Mittal K, et al.Gene expression studies provide clues to the pathogenesis of uterine leiomyoma:new evidence and a systematic review.HumReprod,2005, 20(4):852-63.
[10].Chun-hua ZHANG, Ze-qing WEN, et al. Inhibition of proliferation and transforming growth factors β 3 protein expression by peroxisome proliferators-activated receptor γ ligands in human uterine leiomyoma cells. Chin Med J,2008,121(2):166-171.
[11].Houston KD, CoPland JA, BroaddusRR, et al Inhibition of proliferation and estrogen rceeptor signaling by Peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma.Caneer Res,2003,63(6):1221-7.
[12].Jones SA, Moore LB, Shenk JL, ET AL. The pregnane X receptor:a promiseuous xenobiotic receptor that has diverged during evolution. MolEndoerinal,2000,14(1):27-39.
[13].Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome proliferators-activated receptors (PPARs) and their roles in inflam-mation and cancer [J]. Cell Mol Life Sci,1999,55:932-43
[14].Yu D, Murdoch SJ, Parikh SJ, et al. rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diab Vasc Dis Res,2006,3(3):189-96.
[15].Rios-Vazquez R, Marzoa-Rivas R, Gil-Ortega I. et al. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs.2006,6(4):231-42
[16].Freed MI, Allen A, Jorkasky DK, et al. Systemic exposure to rosiglitazone is unaltered by food. Eur J Clin Pharmacol,1999,55(1):53-56.
[17].Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos,2000,28(7):772-80.
[18]Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Er J Clin Pharmaccl,1999,48(3):424-32.
[19].Thompson-Culkin K, Zussman B, Miller A, et al. Pharmacokinetics of rosiflitazone in patients with end-stage renal disease. J Int Med Res,2002,30(4):391-399.
[20].Stumvoll M, Haring HU. Glitazones:clinical effects and molecular mechanisms. Ann Med, 2002,34(3):217-24.
[21].Ehrmann JJr,Vavrusova N,Collan Y, et al. Peroxisome proliferators activated-receptors(PPARs) in health and disease.Biomed Pad Med Fac Univ Palacky Olomouc Czech Rupub,2002,146(2):11-14.
[22].Wood DE,Thomas A, Devi,et al.Bax cleavage is mediated by calpain during drug induced apoptosis.Oncogene,1998,17:1069-1078.
[23].Kovacs KA,Lengyel F, Kornyei JL,et al. Differential espression of Akt/protein kinase B,bcl-2 and bas proteins in human leiomyoma and myometrium.J Steroid Biochem Mol Biol,2003,87(4250;233-40.
[24].Matsuo H,Maruo T,Samoto T. Increased expression of bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab,1997,82 (1):293-99.
[25].Wu X, Blanck A,OlovssonM, et al. Expression of bcl-2,bcl-x,mcl-l,bax and bak in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause.J Steroid Biochem Mol Biol,2002,80(1):77-83.
[1].Issemannl, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature,1990,347(6294):645-50.
[2].Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996,1302(2):93-109.
[3].Elbrecht A, Chen Y, Cullinan CA, et al. Molecular cloning expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun,1996,224(2):431-37.
[4]Willson TM,Brown PJ, Sternbach DD, et al. The PPARs:from orphan receptors to drug discovery. J Med Chem,2000,43 (4):527-50.
[5].Forman BM, Tontonoz P, Chen J, et al.15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell,1995,83(5):803-12.
[6].Berger J,Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator activated receptor-gamma:binding and activation correlate with antidiabetic actions in db/db mice.Endocrinology.1996.137(10):4189-95.
[7].HOUSEKNECHT KL, COLEBM, STEELE PJ. Peroxisome proliferators-activated receptor gamma and review. Domest Anim Endocrinol,2002,22(1):1-23.
[8].Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol,2002,2(10):748-59.
[9]. Castrillo A,Diaz-Guerra MJ, Hortelano S, et al. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta (12,14)-prostaglandin J (2) in activated murine macro-phages. Mol Cel 1 Biol,2000,20 (5):1692-98.
[10]. Palakurthi SS, Aktas H, Grubissich LM, et al. Anticancer effect s of thiazolidinediones are independent of peroxisome proliferators-activated receptor gamma and mediated by inhibit-tion of translation initiation. Cancer Res,2001,61 (16):6213-18.
[11].Zander T, Kraus JA, Grommes C, et al. Induction of apoptosis in hunman and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem,2002,81(5):1052-60.
[12].杨风光,张志文,辛殿祺,等。曲格列酮诱导肾癌细胞的凋亡.北京大学学报(医学版),2004,36(2)：173-176.
[13].Nagamine M,Okumura T, Tanno S, et al. PPAR γ ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci,2003,94 (4):338-43.
[14].Baek SJ, Wilson LC, His LC, et al. Troglitazone, a peroxisome proliferator-activated receptor γ (PPAR Y) ligand, selectively induces the early growth responser-1 gene independently of PPAR γ. J Biol Chen,2003,278(8):5845-53.
[15].Piva R, Gianferretti P, Ciucci A, et al.15-Deoxy-{Delta} 12,14-prostaglandin J2 induces apoptosis in human malignant B cells:an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood,2005,105 (4):1750-58.
[16].Chung YW, Han DS, Kang EK, et al.Effects of peroxisome proliferators-activated receptor-gamma agonist on Fas-mediated apoptosis in HT229 cells. Korean J Gastroenterol,2003,42 (1):35-41.
[17].Strakova N, Ehrmann J, Dzubak P, et al. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther,2004,309 (3):1239-47.
[18].Han S, Sidell N, Fisher PB, et al. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res, 2004,10(6):1911-19.
[19]. Koga H, Sakisaka S, Harada M, et al. Involvement of p21(WAF1/Cip1), p27 (Kip1), and pl8(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology, 2001,33 (5):1087-97.
[20].潘华锋,陈孝平.Ciglitazone抑制人肝癌HepG2细胞增殖活性的实验研究.中华实验外科杂志,2004,21(8)：934-36.
[21].Kato M, Kusumi T, Tsuchida S, et al. Induction of differentiation and peroxisome prolife.rator-activator receptor γ expression in colon cancer cell lines by troglitazone. J. Cancer Res Clin Oncol,2004,130(2):73-79.
[22].Yoshizumi T, Ohta T, Nionmiya I, et al. Thiazolidine, a perroxisome proliferator-activated receptor-gammaligand, inhibits grows and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol,2004,25(3):631-39.
[23].Ceni E, Mello T, Tarocchi M, et al.Antidiabetic thiazolisinediones induce ductal differentiation but not apoptosis in pancreatic cancer cell. World J Gastroenterol, 2005,11 (8):1122-30.
[24].Zander T, Kraus JA, Grommes C, et al. induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgammma. J Neurochem,2002,81(5):1052-60.
[25]Barak Y, Nel son MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell,1999,4 (4):585-95.
[26]Margeli A, Kouraklis G, Theocharis S. Peroxisome proliferator activated receptor-c (PPAR-c) ligands and angiogenesis. Angiogenesis,2003,6 (3):165-69.
[27]Ferruzzi P, Ceni E, Tarocchi M, et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab,2005,90 (3):1332-39.
[28]Galli A, Ceni E, Crabb DW, et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR-gamma independent mechanisms.Gut,2004,53 (11):1688-97.
[29].Arslan AA, Gold LI, Mittal K, et al.Gene expression studies provide clues to the pathogenesis of uterine leiomyoma:new evidence and a systematic review.HumReprod,2005, 20(4):852-63.
[30].Chun-hua ZHANG, Ze-qing WEN, et al. Inhibition of proliferation and transforming growth factors β 3 protein expression by peroxisome proliferators-activated receptor γ ligands in human uterine leiomyoma cells. Chin Med J,2008,121(2):166-71.
[31].Houston KD, CoPland JA, BroaddusRR, et al Inhibition of proliferation and estrogen rceeptor signaling by Peroxisome proliferator-activated receptor gamma ligands in uterine leiomvoma.Caneer Res,2003,63(6):1221-27
[321Loy CJ, Evelyn S, Lim FK, et al. Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone. Mol Hum Reprod,2005;1:561-66
[33]Han S, Inoue H, Lisa C, et al. Control of COX2 gene expression through PPAR in human cervical cancer cells. Clin Cancer Res,2003,9:4627-4635.
[34]George G, Chen HX, J anet FY, et al.15-hydroxy-eicosate traenoic acidarrests growth of colorectal cancer cell s viaaperoxi some poliferator-activatedreceptor gamma-depengent pat-hway. Intern J Cancer,2003,107:837-843.
[35]阿仙姑·哈斯木,拉莱·苏组克,李巧稚,等.PPAR γ在人子宫肌瘤上皮内瘤样变中 表达及意义.新疆医科大学学报,2007,30(6)：601-603.
[36]Panigraphy D, Singer S, Shen LQ, et al. PPARr ligands inhibit primary tumor growth and metastasis by inhibit ingangio genesis. J Clin Invest,2002,110:923-932.
[37]Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system:Terminology for reporting result s of cervical cytology. JAMA,2002,287:2114-2119.
[38]Walker P, Dexeus S, De Palo G., et al. International Terminology of Colposcopy:An Updated Report From t he International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol,2003.101:175-177.
[39]孔蕾,张家文,于甬华,et al.PPAR、PTEN、P27kipl在雌激素依赖型和非雌激素依赖型子宫内膜癌中的表达及其临床意义.中国妇产科临床杂志,2007,Vol.8,No.6,442-44.
[40].Zhang GY, Ahmed N, Riley C. et al. Enhanced expression of perioxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer. 2005,92(1):113-9.
[41].Sakamoto A, Yokoyama Y, Umemnoto M. et al. Clinical implication of expression of cyclooxygenase-2 and peroxisome perliferator activated-receptor gamma in epithelial ovarian tumours. Br J Cancer.2004,91(4):633-638.